- Baker Brothers’ 13F portfolio value increased from $22.67B to $25.03B this quarter.
- The large stake in BeiGene was increased during the quarter.
- The top three positions are Seattle Genetics, BeiGene, and Incyte Corporation and they add up to almost ~64% of the portfolio.
This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 11/16/2020.
This quarter, Baker Brothers’ 13F portfolio value increased
~10% from ~$22.67B to ~$25.03B. The top three holdings are at ~64% while the
top five holdings are at ~75% of the 13F assets: Seattle Genetics (SGEN),
BeiGene (BGNE), Incyte Corporation (INCY), Acadia Pharma (ACAD), and Alexion
Pharmaceuticals (ALXN).
The spreadsheet below highlights changes to Baker Brothers’
13F holdings in Q3 2020. For a look at how the portfolio has progressed, please
see our previous
update:
To learn more about how to profit from a strategy of
following the best hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little
Guy .
No comments :
Post a Comment